

Special Issue

Advanced Research in Organ-on-a-Chip and Cancer

Message from the Guest Editors

The lack of controllable preclinical models able to faithfully recapitulate the human cancer microenvironment impedes the development of novel therapies and limits our understanding of tumor etiology. Combining compartmentalized microfabricated platforms with advanced tissue engineering methods offers great potential for building biomimetic microfluidic models of human tissues and organs. These so-called ‘organs-on-a-chip’ models have a unique capacity to, in vitro, recreate the biological complexity, mechanochemical cues, and fluid dynamics of native habitats of human cells and tissues, permitting the recapitulation of in vivo phenomena not achievable with traditional preclinical methods. Overall, organ-on-a-chip technology has countless possibilities in academic, industrial and clinical cancer research. We are confident in its ability to continue to offer exciting novel developments and discoveries in upcoming years. We invite all those working in this revolutionary field to contribute to this Special Issue with original research articles, reviews, commentaries and perspectives in all relevant areas of research.

Guest Editors

Prof. Dr. Josep Samitier

Prof. Dr. Rui L. Reis

Dr. David Caballero

Deadline for manuscript submissions

closed (15 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/146208

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)